GLP-1 Weight Loss Drugs Linked to 30% Lower Breast Cancer Risk

Study Findings on Breast Cancer Risk

A large scientific analysis has found that women taking glucagon-like peptide-1 (GLP-1) receptor agonists were approximately 30% less likely to develop breast cancer. This medication class includes widely used drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound.

The research was presented at the American Society of Clinical Oncology's annual meeting in Chicago. One of the primary studies analyzed medical records from approximately 100,000 women between the ages of 45 and 80 who were undergoing breast imaging. After researchers accounted for variables including age, diabetes, obesity, and other risk factors, GLP-1 users maintained a roughly 30% lower risk of developing the disease.

Context of GLP-1 Medications

GLP-1 drugs were originally developed to treat type 2 diabetes. In recent years, they have been adopted by millions of additional users as injections to assist with weight loss.

Medical researchers note that the link between these medications and cancer risk is not unexpected, as obesity is recognized as a risk factor for at least 13 different types of cancer. A separate study involving 86,000 adults with obesity found that GLP-1 users had a 17% lower overall cancer risk, largely attributed to the effects of weight reduction. Additionally, some new data suggests these drugs may be linked to a lower likelihood of cancer spreading to other organs, though this specific finding has not yet been verified by other research.

Limitations and Future Research

Researchers have cautioned that while the findings are promising, they do not yet constitute definitive proof. A key limitation cited is that the study relied on the analysis of existing medical records rather than a randomized clinical trial.

According to researcher McDonald, these results build upon previous years of studies conducted using animals and lab-grown cells. To move beyond observational data, clinical trials are currently being planned to specifically test whether GLP-1 drugs can be used as a tool to prevent breast cancer.